GlassScriptPhysician profile
Erin Cade
NPI 1578128575
$4,737.83
in general payments reported to CMS, 2019-2025
23 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.08 · 2022: $92.36 · 2023: $831 · 2024: $1,918 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,512 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,512.44 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,135.65 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $752.64 | 2023-2025 | |
| Janssen Biotech, INC. | $699.03 | 2022-2025 | Stelara, Tremfya, Remicade |
| Qol Medical, LLC | $321.67 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $273.22 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $242.92 | 2023-2025 | Omvoh |
| Genzyme Corporation | $225.79 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $161.94 | 2022-2023 | |
| Ardelyx, INC. | $132.74 | 2024-2025 | Ibsrela |
| Pharmacosmos Therapeutics INC. | $104.07 | 2025 | Monoferric |
| Phathom Pharmaceuticals, INC. | $99.97 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $98.55 | 2023-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $90.80 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $79.05 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $72.25 | 2023-2024 | Dificid, Zerbaxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.00 | 2022-2024 | Xifaxan |
| Gilead Sciences, INC. | $43.51 | 2025 | |
| Braintree Laboratories, INC. | $38.31 | 2023-2025 | Sutab, Suflave |
| Pharming Healthcare, INC. | $34.57 | 2023 | Ruconest |
| Redhill Biopharma INC. | $24.95 | 2022 | |
| Dynavax Technologies Corporation | $16.58 | 2023 | Heplisav-B |
| Ipsen Biopharmaceuticals, INC | $15.37 | 2025 | Iqirvo |
| Echosens North America, INC. | $10.25 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Cade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.